Transwomen and the Metabolic Syndrome: Is Orchiectomy Protective?

Michael D. Nelson, Lidia S. Szczepaniak, Janet Wei, Edward Szczepaniak, Francisco J. Sánchez, Eric Vilain, Jennifer H. Stern, Richard N. Bergman, C. Noel Bairey Merz, and Deborah J. Clegg

Abstract

Background: Male-to-female transsexual women or transwomen who undergo cross-sex hormone treatments experience increased health-related risks (e.g., increased rates of cardiovascular disease and premature death). Yet, the exact mechanism by which altering biochemistry leads to metabolic impairment remains unclear. While much attention has been paid to cross-sex hormone therapy, little is known about the metabolic risk associated with orchiectomy.

Methods: To address the above limitation, we prospectively enrolled 12 transwomen: 4 who had undergone bilateral orchiectomy and 8 who had not. Both groups were using cross-sex hormones. Glucose tolerance was assessed using a standard 75g oral glucose tolerance test. Hepatic steatosis was assessed by 1H magnetic resonance spectroscopy. The amount of subcutaneous and visceral abdominal fat was determined from a single abdominal axial image at the level between the vertebral L2 and L3 bodies. Baseline venous fasting blood sampling was performed for measurement of hemoglobin A1c, glucose, insulin, sex hormones, and sex hormone binding globulin.

Results: The major novel findings were: (1) orchiectomy and cross-sex hormone therapy is associated with less hepatic steatosis and insulin resistance; (2) orchiectomy may be metabolically protective, and (3) circulating concentrations of sex hormones may be a major determinant of metabolic health in transwomen.

Conclusions: To our knowledge, this is the first study to suggest an independent and protective role of orchiectomy on the metabolic health of transwomen.

Keywords: androgens; estrogens; insulin resistance; metabolic syndrome; orchiectomy; steatosis; transwomen

Introduction

The United States has an estimated 8–16 million people (0.2–0.5% of the population) whose gender identity does not match their biological gender at birth. When the diagnostic criteria are met for gender dysphoria, individuals opt for interventions and procedures aimed at alleviating the incongruence between their gender identity and their biological sex; namely cross-sex hormones and sex-reassignment surgery.

The Endocrine Society cross-sex hormonal therapy guidelines suggest antiandrogen therapy combined with oral or transdermal estrogens to induce feminization for transwomen. Although these recommendations are established using best practice guidelines, little is known about relationships between hormonal and surgical therapy and cardiometabolic health. There are some observations suggesting that cross-sex hormone administration may be associated with the
metabolic syndrome among transwomen; however, the mechanistic underpinnings for these observations remain unclear and the role of orchiectomy unexplored. We hypothesized that cross-sex hormone therapy without orchiectomy would be associated with an adverse cardiometabolic status.

Methods
The study was approved by the institutional review board at Cedars-Sinai Medical Center. All subjects provided written informed consent to participate.

Study participants (n = 12) were recruited from a registry managed by the UCLA Center for Gender-Based Biology. Anthropometric and metabolic data before entry into the study were not annotated. The number of years following sex reassignment did not significantly differ among study participants. Eight of 11 participants were receiving intramuscular injections of estradiol valerate (10–40 mg, biweekly); whereas the other participants were receiving either transdermal estradiol (n = 2) or oral estrogen compounds (n = 1). Antiandrogen therapy (four of eight testes+ participants) consisted of spironolactone orally (100–200 mg/day). Four of the 12 participants had undergone bilateral orchiectomy (testes−) verified by magnetic resonance imaging and confirmed by a clinical radiologist. Exclusion criteria included the following: individuals with type 2 diabetes, age < 18 years, body mass index (BMI) > 44 kg/m², contraindications to magnetic resonance imaging, and use of medications known to alter hepatic triglyceride content.

Anthropometric measurements and OGTT
Height and weight were measured at the time of entry into the study. Fasting blood measurements for lipid profile, hemoglobin A1c, glucose, insulin, adiponectin, and sex hormones were performed. Insulin sensitivity was assessed following an oral glucose tolerance test (OGTT). Blood samples for glucose and insulin were obtained before and 10, 20, 30, 60, 90, 120, and 180 min during the OGTT.

Adiposity
Subcutaneous and visceral adiposity was determined from an axial abdominal image between the vertebral L2 and L3 bodies. Image analysis was performed by a blinded observer using Slice-O-Matic software. BMI was not known before enrollment in this study.

FIG. 1. (A) High resolution image of the upper abdomen showing the region within the upper right hepatic lobe in which measurement of triglyceride (TG) content was obtained. Proton spectrum from the liver is also shown, illustrating the resonance peaks derived from hepatic water and TG. An expanded view of the spectrum is also included, highlighting the resonances from protons in the fatty acid chains. (B) Group average insulin response curves during oral glucose tolerance test. Solid line indicates subjects with testes (Testes+), whereas the dashed line indicates those subjects without testes (Testes−). (C) Individual hepatic TG content for subjects without testes (Testes−) and with testes (Testes+), expressed as ratio of fat to water (%). (D) Relationship between hepatic TG content and insulin sensitivity in all transwomen. *Denotes statistical significance, p < 0.05.
1H MRS of hepatic triglyceride content
Hepatic triglyceride content was quantified using 1H MRS at 3 Tesla. With the participant in the supine position, high-resolution, perpendicular images through the abdomen were collected to locate the liver. The volume for spectroscopic testing was selected at the upper right hepatic lobe using coronal, sagittal, and axial liver images with special attention not to include any visceral fat (Fig. 1A). Large volumes of interest (~8 mL) were used to obtain average hepatic triglyceride levels. Spectroscopic data were collected as volunteers breathed freely, and the 1H MRS signal was triggered at end-expiration. Data were processed as previously described.14–16

Biochemical analysis
Baseline and OGTT. Glucose was measured using a YSI 2300 or 2700 autoanalyzer (Yellow Springs Instruments, Yellow Springs, OH). Insulin was measured using an ELISA (EMD Millipore, Billerica, MA). Fasting glucose and insulin levels were used for homeostasis model assessment of insulin resistance,12 and the composite insulin sensitivity index was estimated from the glucose and insulin concentrations during the OGTT.13 The trapezoidal rule was used to calculate the areas under the curve (AUC) for glucose and insulin during the OGTT. Adiponectin was quantified by ELISA (Millipore Cat# EZHADP-61K).

Sex hormones. Hormone levels were quantified by immunoassay methods. Androstenedione, testosterone, estrone, and estradiol were measured in the same serum aliquot (0.5 mL) by radioimmunoassay following extraction with ethyl acetate:hexane (3:2) and Celite column partition chromatography using ethylene glycol as the stationary phase.14–16 Elution of the steroids off the column was carried out with isooctane, 40% toluene in isooctane, 15% ethyl acetate in isooctane, and 40% ethyl acetate in isooctane, respectively. DHEAS, cortisol, and SHBG were quantified on the Immulite analyzer (Siemens Healthcare Diagnostics, Deerfield, IL). The procedure for the DHEAS and cortisol assays is a solid-phase, competitive, chemiluminescent enzyme immunoassay. Sex hormone-binding globulin (SHBG), for the determination of free (nonprotein bound) estradiol and testosterone, was quantified by solid-phase, two-site chemiluminescent immunoassay on the Immulite analyzer. Free estradiol and testosterone were calculated with a validated algorithm based on derived equations.17,18 The algorithm uses measured concentrations of total estradiol or total testosterone and SHBG, an assumed average concentration of albumin (3.5 g/dL), and the appropriate affinity constants of SHBG and albumin for estradiol or testosterone.

Statistical analysis
Data are reported as mean ± standard error unless otherwise stated. The prespecified primary analysis was comparison between transwomen with testes and those without using a t-test. The Mann–Whitney rank-sum test was used for nonnormally distributed data. Regression analysis assessed specific relationships. Secondary analysis revealed within group differences in circulating sex hormones, further dividing the subjects into three groups: (1) testes−, (2) testes+ with “low” testosterone concentrations, and (3) testes+ with “high” testosterone concentrations. To define differences between these three groups, a

| Table 1. Baseline Characteristics |
|---------------------------------|
|                                |
| **Transsexual women testes**    |
| **Transsexual women testes**    |
| **n**                           |
| 8                               |
| 4                               |
| **Ethnicity, C/H/AA**           |
| 2/0/0                           |
| 2/0/0                           |
| **Age, years**                  |
| 39 ± 10                         |
| 40 ± 5                          |
| **Height, cm**                  |
| 176.0 ± 7.6                    |
| 174.8 ± 6.0                    |
| **Weight, kg**                  |
| 104.7 ± 31.9                   |
| 76.6 ± 8.0                     |
| **BMI, kg/m²**                  |
| 33.3 ± 7.7                     |
| 25.1 ± 2.8                     |
| **Hepatic triglyceride, fat/H₂O** |
| 1.5 ± 0.7                      |
| 8.9 ± 6.8                      |
| **Visceral fat, cm³**           |
| 193.3 ± 117.0                  |
| 79.9 ± 26.6                    |
| **Subcutaneous fat, cm³**       |
| 319.6 ± 120.7                  |
| 129.9 ± 29.3b                  |
| **Whole body area, cm³**        |
| 894.3 ± 349.0                  |
| 560.5 ± 69.8b                   |
| **Total fat area, cm³**         |
| 513.1 ± 226.0                  |
| 209.7 ± 52.7b                   |
| **Visceral fat, %**             |
| 20 ± 7                         |
| 14 ± 3                         |
| **Subcutaneous fat, %**         |
| 36 ± 5                         |
| 23 ± 3b                        |
| **Total fat, %**                |
| 56 ± 4                         |
| 37 ± 5b                        |
| **Total glycated Hgb**          |
| 5.9 ± 0.7                      |
| 5.3 ± 0.6a                     |
| **Hgb, g/dL**                   |
| 5.2 ± 0.4                      |
| 4.8 ± 0.3                      |
| **Fasting glucose, mg/dL**      |
| 91.5 ± 7.5                     |
| 87.9 ± 4.1                     |
| **Fasting insulin, μU/mL**      |
| 19.4 ± 15.6                    |
| 7.7 ± 7.7a                     |
| **HOMA-IR**                     |
| 4.6 ± 3.7                      |
| 1.7 ± 1.8a                     |
| **SHBG, nmol/L**                |
| 643.4 ± 42.6                   |
| 126.5 ± 18.0b                   |
| **Testosterone, ng/dL**         |
| 71.9 ± 7.15                    |
| 16.3 ± 4.8                     |
| **Free testosterone, pg/mL**    |
| 15.2 ± 15.4                    |
| 1.6 ± 0.5b                     |
| **FT + AT, ng/mL**              |
| 37.4 ± 37.7                    |
| 4.0 ± 1.1b                     |
| **Cortisol, μg/dL**             |
| 16.5 ± 5.4                     |
| 14.4 ± 3.9                     |
| **DHEAS, μg/dL**                |
| 106.9 ± 60.3                   |
| 85.7 ± 34.4                    |
| **Androstenedione, pg/mL**      |
| 521.3 ± 202.2                  |
| 531.7 ± 204.0                  |
| **Estrone, pg/mL**              |
| 204.2 ± 181.9                  |
| 256.2 ± 127.9                  |
| **Estradiol, pg/mL**            |
| 209.3 ± 235.0                  |
| 500.7 ± 197.3                  |
| **Free estradiol, pg/mL**       |
| 4.6 ± 5.8                      |
| 7.5 ± 2.8                      |
| **FE2 + AE2, pg/mL**            |
| 117.6 ± 146.7                  |
| 191.1 ± 70.6                   |
| **Adiponectin, μg/mL**          |
| 11.5 ± 6.7                     |
| 5.9 ± 4.2                      |

Data reported as mean ± SD. p-Value indicates differences between groups with and without testes. *p < 0.10. **p < 0.05.

AE2, albumin-bound estradiol; AT, albumin-bound testosterone; BMI, body mass index; C/H/AA, Caucasian/Hispanic/African American; FE2, free estradiol; FT, free testosterone; Hgb, hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; SHBG, sex hormone-binding globulin.
one-way analysis of variance was used. Rank sum tests were used if data were not normally distributed. To determine the overall influence of BMI and sex hormones on specific metabolic outcome variables, linear regression modeling was used, with log transformation applied to skewed distributions.

Results

General group characteristics are presented in Table 1 for 12 transwomen—8 with testes (testes\(^+\)) and 4 with orchiectomy (testes\(^-\)). Participants did not differ by age, hemoglobin A\(_1c\), glucose, or glaucinated hemoglobin. Testes\(^+\) transwomen trended toward having a higher BMI \((p < 0.1)\), but had significantly higher total, and subcutaneous adiposity when compared to testes\(^-\) transwomen \((p < 0.05)\) (Table 1).

Testes\(^+\) transwomen tended to have an overall heightened insulin response to the glucose challenge (Fig. 1B), when compared to testes\(^-\) transwomen. Despite similar plasma glucose levels during the OGTT \((17823 ± 859 vs. 20380 ± 1263 \text{ mg/dL/180 min}, p < 0.21)\), the AUC for insulin was more than twofold higher in testes\(^+\) transwomen compared to testes\(^-\) transwomen \((p < 0.05)\) (Table 1).

Testes\(^+\) transwomen had higher levels of testosterone, free testosterone and bioavailable testosterone (free testosterone plus albumin-bound testosterone), and lower levels of sex hormone-binding globulin, compared to testes\(^-\) transwomen (Table 1). In addition, estradiol was lower in the testes\(^+\) transwomen compared to testes\(^-\) transwomen (Table 1). The groups did not differ in cortisol, DHEAS, androstenedione, or estrone levels (Table 1).

As expected, serum sex-hormone levels differed between testes\(^+\) and testes\(^-\) transwomen. Testes\(^+\) transwomen had higher levels of testosterone, free testosterone and bioavailable testosterone (free testosterone plus albumin-bound testosterone), and lower levels of sex hormone-binding globulin, compared to testes\(^-\) transwomen (Table 1). In addition, estradiol was lower in the testes\(^+\) transwomen compared to testes\(^-\) transwomen (Table 1). The groups did not differ in cortisol, DHEAS, androstenedione, or estrone levels (Table 1).

In addition, we found significant within-group differences, independent of hormonal therapy. In particular, four of the eight testes\(^+\) transwomen had significantly higher levels of testosterone when compared to the remaining testes\(^+\) or testes\(^-\) transwomen (Fig. 2A–C, High T group). Moreover, the four transwomen with the highest testosterone levels (High T group) also had the lowest levels of estradiol \((126.5 ± 9.0, 95.1 ± 19.2, 33.4 ± 7.3 \text{ nmol/L}; \text{testes}^-, \text{testes}^+ \text{low T, testes}^+ \text{high T}, \text{respectively})\). As a result, the testosterone-to-estradiol ratio was significantly elevated in the High T group (by 53 times), when compared to the other two groups (Fig. 2C).

Importantly, transwomen with the highest levels of testosterone also tended to have the highest hepatic steatosis (Fig. 3A) and insulin resistance (Fig. 3B). One participant (open circle, Fig. 3) with the highest hepatic steatosis in the “Testes\(^+\), Low T” group also had the greatest insulin resistance within that group, further strengthening the potential mechanistic relationship between these two outcomes in this cohort.

To further differentiate the influence of body adiposity and circulating testosterone on hepatic steatosis...
and insulin resistance, we performed linear regression modeling. A regression of insulin sensitivity on both testosterone and BMI showed a significant model fit, but neither explanatory factor was found to be individually significant ($R^2 = 0.4989$, $p = 0.045$). In contrast, a regression of hepatic steatosis on both testosterone and BMI showed a significant model fit, with only testosterone being individually significant ($R^2 = 0.67$, $p = 0.012$).

**Discussion**

To our knowledge, this is the first study to specifically compare transwomen with and without orchiectomy related to cardiometabolic measures, including hepatic steatosis, insulin sensitivity, and serum hormonal levels. We report three major new findings: (1) orchiectomy and cross-sex therapy is associated with less hepatic steatosis and insulin resistance when compared to cross-sex hormone therapy alone, (2) insulin resistance is positively related to hepatic steatosis—a finding not previously reported in this population, and (3) elevations in serum-free testosterone levels are positively associated with hepatic steatosis and insulin resistance in transwomen. Taken together, these data suggest a balance between free testosterone levels, and estradiol may represent an important biomarker in transwomen for cardiometabolic risk.

The relationship between serum sex hormones and cardiometabolic health is supported by the subset of testes$^+$ transwomen who had elevated free testosterone levels compared to the other participants. These participants also had the highest levels of hepatic steatosis, the greatest measured insulin resistance, and the lowest levels of estrogens and SHBG. Further work is needed to determine if these factors are mechanistically related or causally associated. Importantly, we observed that orchiectomy was associated with less liver steatosis and insulin sensitivity, despite cross-sex hormone treatment. Admittedly, the duration, dosage, and timing of cross hormone therapy did differ among our subjects; however, our sample size is small enough that we were unable to power the study adequately to factor in these potential confounding variables. Circulating levels of adiponectin, an insulin sensitizing, antiapoptotic, and anti-inflammatory adipokine, is typically inversely correlated with adiposity and is higher in women than men. While the mechanism for this sex difference is not entirely elucidated, circulating testosterone has been shown to inhibit the secretion of adiponectin from the adipocyte.$^{20,21}$

The ratio of testosterone and estradiol has been proposed as a marker of cardiometabolic health.$^{22–24}$ In a study by Gong et al.$^{22}$ a high testosterone-to-estradiol ratio was associated with cerebrovascular disease. Likewise, Zheng et al. found the testosterone-to-estradiol ratio to be nearly twice higher in men with coronary heart disease, compared to age-matched controls.$^{24}$ In
our study, we found that transsexual women with an elevated testosterone had the lowest levels of estradiol, resulting in a testosterone-to-estradiol ratio 53 times higher than either of the other two groups, suggesting that the balance between testosterone and estradiol may be more important than absolute levels of either hormone for cardiometabolic health. Importantly, the duration and type of estrogen supplementation did not differ across the groups; however, utilization of estrogens was self-reported.

This clinical case series is not without limitation. First, our small sample size precludes definitive conclusions and must be interpreted with caution. However, we observed group differences, despite the small sample size, suggesting that the associations—if real—are very robust. Our study is cross-sectional, thus precluding us from making causative conclusions regarding the relationship and the mechanisms involved. In addition, information such as metabolic health and BMI before gender reassignment and enrollment in our study is largely unknown and admittedly may confound interpretations of our findings. We therefore believe that our small observational trial provides novel insight that requires larger longitudinal investigations to confirm our initial observations and to specifically evaluate the prognostic importance of these findings on the cardiometabolic health and cardiovascular disease events in transwomen. BMI was higher in the testes+ transwomen; however, because the transwomen with the highest testosterone levels also had the highest BMI and subcutaneous and total fat percentage, we find these data important because normally high BMI is associated with low testosterone, yet in the group with the highest testosterone, we observed the highest BMI. Admittedly, we do not know the BMI of the individuals at the time of gender reassignment if there is any impact of this on our results.

Perspectives and Conclusions
The Guidelines on Endocrine Treatment of Transsexuals concludes by recommending the need for rigorous evaluations of the safety, effectiveness, and long-term impact of endocrine protocols in transgenders.25 In this study, we show that (1) orchiectomy may be metabolically protective and (2) the circulating ratio of sex hormones may be a major determinant of metabolic health in transwomen. Future research is indeed warranted. Importantly, additional longitudinal and prospective studies should be conducted in this understudied population. Implications from our findings may suggest in those individuals who elect to maintain their testes; additional pharmacology may be required to suppress endogenous T levels, such as GnRH antagonists, to maintain a more favorable T/E ratio and enhance cardiometabolic health.

Author Disclosure Statement
No competing financial interests exist.

References
1. California Department of Finance. Race/Ethnic Population with Age and Sex Detail, 2000–2050. Sacramento, CA, 2007.
2. Conron K, Scott G, Stowell G, Landers S. Transgender health in Massachusetts: results from a household probability sample of adults. Am J Public Health. 2012;102:118–122.
3. Gates G. How Many People Are Lesbian, Gay, Bisexual, and Transgender? Los Angeles, CA: UCLA School of Law, The Williams Institute, 2011.
4. Reed B, Rhodes S, Schofield P, Wylie K. Gender Variance in the UK: Prevalence, Incidence, Growth, and Geographic Distribution. United Kingdom: Gender Identity Research and Education Society, 2009.
5. Horton MA. The Prevalence of SRS Among US Residents. Austin, Texas: Out & Equal Workplace Summit, 2008.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, 2013.
7. Gooren LJ, Giltay EJ, Buuck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93:19–25.
8. Abate N, Garg A, Coleman R, et al. Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am J Clin Nutr. 1997;65:403–408.
9. Szczepaniak LS, Nurengberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol. 2005;288:E462–E468.
10. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H NMR spectroscopy: validation in vivo. Am J Physiol. 1999;276:E977–E989.
11. Szczepaniak LS, Victor RG, Mathur R, et al. Pancreatic steatosis and its relationship to beta-cell dysfunction in humans. Diabetes Care. 2012;7:1–7.
12. Mathews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1992;15:1462–1470.
14. Goebelsmann U, Horton R, Mestman J, et al. Male pseudohermaphroditism due to testicular 17-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1973;36:867.
15. Goebelsmann U, Arce J, Thorneycroft L, Mishell DJ. Serum testosterone concentrations in women throughout the menstrual cycle and following hCG administration. Am J Obstet Gynecol. 1974;119:445.
16. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 1999;6:165–173.
17. Muntz S, Gey S, Dechaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002;11:1065–1071.
18. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672.
19. Bottner A, Kratsch J, Muller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004;89:4053–4061.
20. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51:2734–2741.
21. Xu A, Chan KW, Hoo RLC, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–18080.

22. Gong Y, Xiao H, Li C, et al. Elevated T/E2 ratio is associated with an increased risk of cerebrovascular disease in elderly men. PLoS One. 2013;8:e61598.

23. Myking OLE, Aakvaag ASBJ, Digranes O. Androgen/oestrogen imbalance in men with chronic alcoholism and fatty liver. Alcohol Alcohol. 1987;22:7–15.

24. Zheng H, Li Y, Dai W, et al. Imbalance of testosterone/estradiol promotes male CHD development. Biomed Mater Eng. 2012;22:179–185.

25. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal H, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:3132–3154.